171 - New Antibiotics, Untapped Potential: Exploring the Underuse of Recently Approved Agents

Tuesday, October 21, 2025

3:15 PM - 4:30 PM US ET

Location: B302-B304

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

David Cluck, PharmD, FIDSA, BCPS, BCIDP, AAHIVP (he/him/his)

Associate Professor of Pharmacy Practice
Pharmacy Practice
ETSU Bill Gatton College of Pharmacy
Johnson City, TN, United States
TL

Thomas Lodise, Jr., PharmD, PhD

Professor, Pharmacy Practice
Albany College of Pharmacy and Health Sciences, Stratton, VA, United States
Stratton, VA, United States

Faculty(s)

Amy Carr, PharmD, BCIDP

Clinical Pharmacy Manager
Pharmacy
AdventHealth Orlando
Orlando, FL, United States
Christine Vu, PharmD (she/her/hers)

Infectious diseases pharmacist
Jackson Memorial Hospital
Miami, FL, United States
Wendi Drummond, DO, MPH (she/her/hers)

Infectious Disease Consultant, Medical Director, Ambulatory Infection Prevention
Providence Health
Portland, OR, United States

Disclosure(s):

David B. Cluck, PharmD, FIDSA, BCPS, BCIDP, AAHIVP: Astellas, Inc: Advisor/Consultant

Thomas Lodise, PharmD, PhD, Jr.: GSK: Advisor/Consultant

Amy L. Carr, PharmD, BCIDP: Innoviva Speciality Therapeutics: Advisor/Consultant

Christine A. Vu, PharmD: No financial relationships to disclose.

Wendi K. Drummond, DO, MPH: Insmed Incorporated: Advisor/Consultant, Honoraria

Learning Objectives:

At the conclusion of this session, participants will be able to:

recognize situations where new antimicrobial agents may optimize clinical outcomes;
describe the place in therapy of imipenem-relebactam relative to other novel beta-lactam/beta-lactamase inhibitors;
select clinical situations where tedizolid may be considered over linezolid;
compare and contrast omadacycline and eravacycline for infections beyond non-tuberculous mycobacteria.

Presentations:

3:15 PM - 3:40 PM US ET

Real-World Experience With Imipenem-Relebactam
Speaker: Christine A. Vu, PharmD (she/her/hers) – Jackson Memorial Hospital
3:40 PM - 4:05 PM US ET

When Should You Consider Tedizolid?
Speaker: Wendi K. Drummond, DO, MPH (she/her/hers) – Providence Health
4:05 PM - 4:30 PM US ET

Utility of Eravacycline and Omadacycline Beyond Non-Tuberculous Mycobacterial Infections
Speaker: Amy L. Carr, PharmD, BCIDP – AdventHealth Orlando